Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to protect kidney transplants from early failure

NCT ID NCT06855758

Disease control Sponsor: Beijing Friendship Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This study tests whether adding terlipressin to standard care helps maintain stable blood pressure during kidney transplant surgery. Researchers will compare two groups of 150 adults: one receiving terlipressin plus dobutamine, the other dobutamine alone. The main goal is to see if terlipressin reduces the need for dialysis in the first week after transplant.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
terlipressin
What this could lead to
If it works, this could improve blood pressure control during kidney transplant surgery and reduce the need for dialysis shortly after transplant.
What could go wrong
This is a small, early-stage trial (150 people) testing a drug already used for other conditions. The benefit may be modest or not confirmed in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with end-stage renal disease aged 18 years or above Exclusion Criteria: * simultaneous multiple organ transplantation * known allergy to study medication * known pregnancy status * cancellation of surgery due to grafts or personal reasons * persistent severe preoperative hypertension that may not require intraoperative supportive therapy with vasoactive medications * any other reason that the supervising physician or the anesthesiologist on duty think the patient is not suitable for the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Delayed graft function are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Delayed Graft Function end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Delayed graft function Intraoperative hypotension Kidney transplant

Contacts and locations

Locations

  • Beijing Friendship Hospital

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.